125 related articles for article (PubMed ID: 8831040)
1. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure.
Millichap J; Ristow TA; Noskin GA; Peterson LR
Diagn Microbiol Infect Dis; 1996 May; 25(1):15-20. PubMed ID: 8831040
[TBL] [Abstract][Full Text] [Related]
2. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
4. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
Lorian V; Fernandes F
Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
[TBL] [Abstract][Full Text] [Related]
5. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
[TBL] [Abstract][Full Text] [Related]
6. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Aeschlimann JR; Zervos MJ; Rybak MJ
Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
[TBL] [Abstract][Full Text] [Related]
9. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
Lorian V; Fernandes F
J Antimicrob Chemother; 1997 May; 39 Suppl A():63-6. PubMed ID: 9511065
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
11. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
[TBL] [Abstract][Full Text] [Related]
12. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
[TBL] [Abstract][Full Text] [Related]
13. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.
Herrera-Insúa I; Jacques-Palaz K; Murray BE; Rakita RM
Antimicrob Agents Chemother; 1996 Apr; 40(4):886-90. PubMed ID: 8849245
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium.
Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW
Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691
[TBL] [Abstract][Full Text] [Related]
15. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.
McDonald LC; Rossiter S; Mackinson C; Wang YY; Johnson S; Sullivan M; Sokolow R; DeBess E; Gilbert L; Benson JA; Hill B; Angulo FJ
N Engl J Med; 2001 Oct; 345(16):1155-60. PubMed ID: 11642231
[TBL] [Abstract][Full Text] [Related]
16. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
Matsumura SO; Louie L; Louie M; Simor AE
Antimicrob Agents Chemother; 1999 Nov; 43(11):2776-9. PubMed ID: 10543762
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
Jamjian C; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
20. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
